Moderna says its RSV vaccine for older adults is 84% effective at preventing serious illness.
Adult patients in the clinical trial appeared to tolerate the vaccine well and there were no safety concerns identified, the data showed.
The company said it will ask the U.S. Food and Drug Administration for approval in the first half of 2023.Pharmaceutical companies Pfizer and GSK have also announced promising results for their respective RSV vaccines in older adults. The FDA is expected to decide whether or not to approve both vaccines in May 2023.
There is currently no approved RSV vaccine for any age group, but pharmaceutical companies -- including Moderna, Pfizer and GSK -- have seen promising results in late-stage trials. In this Feb. 13, 2021, file photo, the headquarters of pharmaceutical company Moderna is shown in Cambridge, Mass.Cases of RSV began appearing earlier than usual this year across the United States, according to the Centers for Disease Control and Prevention,Symptoms can include fever, coughing, runny nose, sneezing, wheezing and a decrease in appetite, per the CDC.
RSV leads to mild illness in most people but can cause severe illness in some young children and older adults.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna says RSV vaccine is 84% effective at preventing disease in older adultsRSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the CDC.
Read more »
Moderna says RSV vaccine 84% effective at preventing symptoms in older adultsModerna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.
Read more »
Moderna Reports RSV Vaccine Cuts Risk of Respiratory Diseases in Older AdultsAn RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said
Read more »
Moderna’s RSV Shot Prevents Most Cases in Older PeopleModerna Inc.’s vaccine against RSV was highly effective in preventing the lung disease in older people, paving the way for the company to seek its first...
Read more »
Moderna’s RSV Vaccine Reduces Risk of Respiratory Diseases, Study FindsAn RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said
Read more »
Packing heat: TSA busts San Antonio airport traveler with 84 mm weaponAn undeclared large caliber firearm found in baggage at the San Antonio airport prompts...
Read more »